Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) CEO Anthony Tennyson ✅ RICH TV LIVE – February 3, 2022 – #awaknlifesciences #interview #richtvlive #business #news #finance #education #entertainment #stocks #trading #ceo #anthonytennyson #psychedelics
Hey guys how you doing this is your boy rich from rich tv live and you too can join the club at richpixdaily.com where you can learn how to win and trade hi how’s everybody doing today i’m your host rich here we have a rich tv live with our very special guest the ceo of awaken life sciences anthony tennyson how you doing today anthony uh rich i’m doing really
Well it’s great to speak to you and it’s even better to speak to your audience thank you for having me my pleasure really excited to speak with you today and learn more about your company my first question for those who are just discovering awaken life sciences can you tell us a little bit about the company i’m happy to um we’re awakened life scientists we’re a
Publicly traded biotechnology company so we’re public traded uh in canada on the neo exchange and the otcqb and the us and our core purpose the thing that gets us going every single day is we’re addressing addiction by developing and delivering revolutionary new treatments that are inspired by psychedelics but really we’re pushing the envelope on a developing
And delivering revolutionary treatments for the biggest unmet medical need of modern times now as a biotech company you have a strong focus on addiction why is that and just as i mentioned there it’s the biggest need of modern times rich and 20 of the population of the planet suffer from a substance addiction and another many hundreds of millions of people
Suffer with behavioral addictions so you’ve got substance addictions like alcohol and behavioral addictions like gambling and when you look around at industries that warrant disruption or that are ripe for disruption the addiction treatment industry is one of those industries it’s worth many many billions of dollars per annum so about 15 billion billion dollars
Per annum is spent on treatments for addiction and about 140 billion dollars which 140 billion dollars is spent on rehab and recovery do you know what the average success rate is by 25 for alcohol addiction about 20 for tobacco and about 5 for opioid addiction so this is a massive addict massive industry that’s deeply underperforming and that is ripe for
Disruption and we’re the company that is going to disrupt that industry now you just released the results of what looks like a groundbreaking phase 2a b clinical trial which was ketamine assisted therapy for alcohol use disorder can you tell us more about this and what does it mean happy to tell you more about this it was a trial it’s a phase two a b trial so
Mid-ranking trial from pre-clinical you got phase three and then your marketing authorization it’s running the uk the results were groundbreaking and the people coming into this trial were abstinent so not drinking on average two percent of the time so two in a hundred days they were sober those that went through the ketamine assisted therapy the proprietary
Ketamine assisted therapy designed by our team were sober on average 86 of the time in the six months following treatment so going from sober two percent of the time to sober 86 percent of the time after treatment that’s groundbreaking and when you stack that up against an industry standard of sober 25 percent of the time we are on the cusp of disrupting the
Addiction treatment industry which is valued at many many billions of dollars per annum i’ve also read a bit about your behavioral addictions ketamine study which you have just expanded considerably can you tell us about this happy too um so the approach that we’re taking to to treating addiction is led by someone called professor david nutt professor david
Nutt is the global authority in addiction research he’s one of the top three researchers globally he’s written 400 papers 20 books he was an advisor to the uk state on drug policy reform and he’s had a department in imperial college london the approach that we’re taking to treat addiction is instead of focusing on individual receptor sites we’re focusing on
Disrupting the brain circuits that house addictive behaviors so at a very very simple level there’s three levels to your brain lower level which is reward memory and prediction prediction of pleasure mid level which is salience attribution and driver and upper level which is your mind human cognition as i like to call it the analogy i use is the lower and mid
Level functions they’re the hardware and the mind is the software and what happens in an addictive brain is the mind the software loses control over the hardware and hardware takes takes over control and that’s why you hear people rich say i don’t know why i went back drinking i just found myself in the pub i don’t know why i was back in the bookies or back
Placing bets i don’t know why i was watching pornography even though all of these things are really damaging to me as an individual my family my communities my career and so the approach that we’re taking has been driven by david and what we’re doing is we’re using psychedelic drugs like ketamine and mdma and are actually developing our own compounds as well
But we’re using those to disrupt the brain circuits that house the addictive behaviors and in the space that that disruption provides we’re coming in with proprietary psychotherapy so we’re using drugs and therapies together in a unique revolutionary approach to treating addiction that approach gives us the ability to treat both substance addictions like
Behavior like um alcohol addiction and behavioral addictions like gambling and when you look at gambling disorder there’s 400 million people in the world are affected by alcohol youth disorder it’s another 450 million people affected by gambling disorder up to 300 million people affected by a compulsive sexual behavior which includes pornography addiction so
Not only is substance addiction a massive massive problem that’s deeply underserved by the incumbent industry behavior addictions are equally as big a problem and so we’re running the first studies in the world to develop a pharmacological treatment so a drug-based treatment for behavioral addictions we’re really excited about the progress that we’re making and
We’re looking forward to making some substantial announcements in due course about the progress that we’re making and the hope that we aim to provide for individuals families and communities so poorly affected by gambling addiction and other behavioral addictions can you let the audience know why is awaken a good investment opportunity for them in your opinion
And so awaken is a is a good investment opportunity when you stack us up rich against other players in the industry who have research at the se at the maturity that we do so we are active in phase 2b with ketamine for alcohol use disorder active in phase 2a for mdma for alcohol use disorder and developing our own drugs and working with behavioral addictions
You stack us up against that the only other companies at this level are compass and mindnet and when you see the delta between our markup and their mark cap you see that there is a significant opportunity for material shareholder value creation with awaken you then stack that up and alongside the catalysts the material catalyst that we have coming down the
Track and you’ll see that this really is a company that has potential to grow we’ve got announcements coming down the track about moving our phase 2b clinical trial for ketamine for alcohol use disorder into phase 3 in the uk as part of a strategy to secure marketing authorization for ketamine assisted therapy street alcohol use disorder in the uk which is
A 60 million person economy and a two trillion dollar sorry 60 million person country and a two trillion dollar a year uh gdp territory we’ve also got material announcements coming down the track about the development of ketamine as an intervention to treat behavior addictions mdma to move from phase 2a to phase 2b the identification of a lead and a backup
For our drug development program which you’re going to bring into lead optimization and that’s just what we’re doing on the r d side of the business rich we’re a biotech company but we’ve got revenue today we’ve got two clinics open and generating revenue in the uk and norway today with a third one to come in the next few weeks and then on top of that we’re
Actually going to be licensing the ip from the phase 2b ketamine trial into the north american addiction industry starting in q2 this year so a biotech company that we believe is undervalued with a strong pipeline of catalyst events coming down the track line with revenue starting today and another revenue stream to start in q2 this year so we think there’s
Interesting things to come from this company now awaken recently announced that the company has partnered with maps for mdma assisted therapies for treatment of alcohol use disorder in europe could you please break this down a little for us and what it means for the company absolutely happy to so our mo our modus operandi for our research biotech business is
To acquire assets partner with leaders to accelerate towards a positive outcome so for the ketamine for alcohol use disorder we have acquired the ip from the university college university of exeter we’re partnering with the nhs to bring it forward into a phase three for mgma assisted therapy we’ve acquired the ip from a phase 2a trial from imperial college
In london which is one of the world’s leading research institutes for psychedelics and we’ve partnered with maps one of the leading companies in the world working with mdma for ptsd in order to accelerate this research from phase 2a to phase 2b and on to a phase 3 and marketing authorization for mdma assisted therapy to treat alcohol use disorder in europe
There’s 750 million people in europe when you take in the total geographical area so it’s about 2x the size of the us with about the same number of people drinking too much and the same problem so you get a size of the opportunity so we’re partnering with maps because they know as much about mdma as any other company in the world and so we’re partnering with
Them to improve the probability of success for our research and to reduce the timeline to marketing authorization for mdma assisted therapy for alcohol use disorder to treat in the uk eu and wider europe and we think that is a really really good way to de-risk that for our for the company and therefore increase the probability of success for the company and
Therefore for shareholders anthony what is the best way to get in touch with the company for anyone who has any questions best way for anyone to get into touch the company is just contact me it’s a very easy easy email address it’s anthony at awakenlifesciences.com and awaken is just about a w a k n so awaken life sciences dot com more than happy to field uh
To field emails and uh if people want to you know set up a conf call and stuff like that happy to have a chat with them as well super excited to have you on the show today ceo of awakened life sciences anthony tennyson now i must remind everyone that rich tv live is strictly for information and education purposes please do your due diligence do your research
Before you invest in anything we talk about or discuss here on rich tv live in saying that this is a company with a tight float it’s a company that i believe is undervalued underappreciated underexposed thank you for joining us today anthony and we wish you all the best of luck rich thank you very much my pleasure thank you for watching everybody if you liked
The video smash the like button comment down below share the video everywhere and subscribe if you’re not winning you’re probably not watching bring in the winners and we’ll bring them to you first thank you for watching everybody have a nice day you
Transcribed from video
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) CEO Anthony Tennyson ✅ RICH TV LIVE By RICH TV LIVE
